The data suggests that a combination of a prognostic signature and chemosentivity data from pre-clinical breast cancer cell lines can prospectively predict chemotherapy sensitivity in individual patients with HER2- breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.